Last reviewed · How we verify
NCT04693026
Efficacy of Ramdicivir and Baricitinib for the Treatment of Severe COVID 19 Patients
Phase 3 trial testing Remdesivir in Covid19 in 150 participants. Status unknown.
15 February 2021
Quick facts
| Lead sponsor | M Abdur Rahim Medical College and Hospital |
|---|---|
| Phase | Phase 3 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 150 |
| Start date | 10 September 2020 |
| Primary completion | 15 February 2021 |
| Estimated completion | 5 March 2021 |
| Sites | 1 location across Bangladesh |
Drugs / interventions tested
- Remdesivir (remdesivir) — full drug profile →
- Baricitinib (baricitinib) — full drug profile →
- Tocilizumab (tocilizumab) — full drug profile →
Conditions studied
- Covid19 — all drugs for Covid19 →
- Covid-19 ARDS — all drugs for Covid-19 ARDS →
Sponsor
M Abdur Rahim Medical College and Hospital
Who can join
Eligibility, any sex, with Covid19 or Covid-19 ARDS. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study was designed to evaluate the efficacy of Remdesivir and Baricitinib combination therapy for the treatment of severe Acute Respiratory Distress Syndrome (ARDS) caused by Coronavirus disease 2019 (COVID-19). Our aim is to compare the outcome of the "Remdesivir + Baricitinib" combination against "Remdesivir + Tocilizumab" therapy and find the best option for the management of ARDS in COVID-19 patients.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.
Drożdżal S, Rosik J, Lechowicz K, Machaj F, et al · · 2021 · cited 186× · PMID 34991982 · DOI 10.1016/j.drup.2021.100794 -
Remdesivir for the treatment of COVID-19.
Ansems K, Grundeis F, Dahms K, Mikolajewska A, et al · · 2021 · cited 89× · PMID 34350582 · DOI 10.1002/14651858.cd014962 -
Remdesivir for the treatment of COVID-19.
Grundeis F, Ansems K, Dahms K, Thieme V, et al · · 2023 · cited 55× · PMID 36695483 · DOI 10.1002/14651858.cd014962.pub2 -
Immunotherapy of COVID-19: Inside and Beyond IL-6 Signalling.
Zizzo G, Tamburello A, Castelnovo L, Laria A, et al · · 2022 · cited 55× · PMID 35340805 · DOI 10.3389/fimmu.2022.795315 -
Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses.
White JM, Schiffer JT, Bender Ignacio RA, Xu S, et al · · 2021 · cited 53× · PMID 34933447 · DOI 10.1128/mbio.03347-21 -
Cytokine Storm Syndrome in SARS-CoV-2 Infections: A Functional Role of Mast Cells.
Hafezi B, Chan L, Knapp JP, Karimi N, et al · · 2021 · cited 41× · PMID 34359931 · DOI 10.3390/cells10071761 -
Calming the cytokine storm of COVID-19 through inhibition of JAK2/STAT3 signaling.
Gajjela BK, Zhou MM. · · 2022 · cited 38× · PMID 34743903 · DOI 10.1016/j.drudis.2021.10.016 -
Janus kinase inhibitors for the treatment of COVID-19.
Kramer A, Prinz C, Fichtner F, Fischer AL, et al · · 2022 · cited 34× · PMID 35695334 · DOI 10.1002/14651858.cd015209
Verify or expand the search:
- PubMed search for NCT04693026
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Remdesivir
Trials testing the same drug.
- NCT06817889 — Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals · Phase 2 · recruiting
- NCT05911906 — An Open-label, Clinical Feasibility Study of the Efficacy of Remdesivir for Long-COVID. · Phase 4 · completed
- NCT06860282 — A Study of CX2101A Enteric-Coated Tablets in Healthy Chinese Adult Subjects · Phase 1 · completed
- NCT05502081 — Clinical Study to Compare Efficacy and Safety of Casirivimab and Imdevimab Combination, Remdesivir and Favipravir in Hos · Phase 4 · completed
- NCT05780541 — PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) · Phase 3 · terminated
Other recruiting trials for Covid19
Currently open trials in the same condition.
- NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
- NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
- NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
- NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
- NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting
Other M Abdur Rahim Medical College and Hospital trials
Trials by the same sponsor.
- NCT04678739 — Efficacy and Safety of Remdesivir and Tociluzumab for the Management of Severe COVID-19: A Randomized Controlled Trial · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04693026 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by M Abdur Rahim Medical College and Hospital
- Last refreshed: 5 January 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04693026.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing